A Phase III Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007/2008 in People Aged 18 Years or Above

NCT00476307 Phase 3 COMPLETED

This study is designed to test the immunogenicity and reactogenicity of the Fluarix™/Influsplit SSW® containing the influenza strains recommended for the 2007-2008 season.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 3
Status	COMPLETED
Enrolment	120
Start date	2007-06
Completion	2007-07

Conditions

• Influenza

Interventions

• Fluarix™/Influsplit SSW® 2007/2008

Primary outcomes

• Immune response 21 days post vaccination

Countries

Germany